Baseline characteristics of patients enrolled in the study
| Characteristics . | ATRA + LD-RTX (n = 112) . | LD-RTX (n = 56) . |
|---|---|---|
| Age (y), median (IQR) | 46.0 (36.0-55.8) | 44.5 (36.0-58.0) |
| Male, n (%) | 59 (52.7) | 24 (42.9) |
| Platelet count (109/L), median (IQR) | 17.0 (14.0-21.0) | 19.0 (14.0-25.0) |
| Duration of ITP (mo), median (IQR) | 20.0 (15.0-32.8) | 20.5 (15.0-27.0) |
| Previous treatments, n (%) | ||
| Corticosteroids | 112 (100.0) | 56 (100.0) |
| IVIG | 20 (17.9) | 14 (25.0) |
| Vincristine | 2 (1.8) | 3 (5.4) |
| rhTPO | 21 (18.8) | 8 (14.3) |
| Cyclosporin | 12 (10.7) | 9 (16.1) |
| Danazol | 21 (18.8) | 15 (26.8) |
| Azathioprine | 4 (3.6) | 3 (5.4) |
| Mycophenolate mofetil | 8 (7.1) | 8 (14.3) |
| Splenectomy | 1 (0.9) | 1 (1.8) |
| Herbs | 7 (6.3) | 9 (16.1) |
| Bleeding score, % (n) | ||
| 0 | 53 (47.3) | 31 (55.4) |
| 1 | 40 (35.7) | 17 (30.4) |
| 2 | 11 (9.8) | 5 (8.9) |
| 3 | 5 (4.5) | 2 (3.6) |
| 4 | 3 (2.7) | 1 (1.8) |
| Characteristics . | ATRA + LD-RTX (n = 112) . | LD-RTX (n = 56) . |
|---|---|---|
| Age (y), median (IQR) | 46.0 (36.0-55.8) | 44.5 (36.0-58.0) |
| Male, n (%) | 59 (52.7) | 24 (42.9) |
| Platelet count (109/L), median (IQR) | 17.0 (14.0-21.0) | 19.0 (14.0-25.0) |
| Duration of ITP (mo), median (IQR) | 20.0 (15.0-32.8) | 20.5 (15.0-27.0) |
| Previous treatments, n (%) | ||
| Corticosteroids | 112 (100.0) | 56 (100.0) |
| IVIG | 20 (17.9) | 14 (25.0) |
| Vincristine | 2 (1.8) | 3 (5.4) |
| rhTPO | 21 (18.8) | 8 (14.3) |
| Cyclosporin | 12 (10.7) | 9 (16.1) |
| Danazol | 21 (18.8) | 15 (26.8) |
| Azathioprine | 4 (3.6) | 3 (5.4) |
| Mycophenolate mofetil | 8 (7.1) | 8 (14.3) |
| Splenectomy | 1 (0.9) | 1 (1.8) |
| Herbs | 7 (6.3) | 9 (16.1) |
| Bleeding score, % (n) | ||
| 0 | 53 (47.3) | 31 (55.4) |
| 1 | 40 (35.7) | 17 (30.4) |
| 2 | 11 (9.8) | 5 (8.9) |
| 3 | 5 (4.5) | 2 (3.6) |
| 4 | 3 (2.7) | 1 (1.8) |
rhTPO, recombinant human thrombopoietin.